Elevated FAM3C promotes cell epithelial– mesenchymal transition and cell migration in gastric cancer

Background Tumor metastasis is an important factor in treatment failure for advanced gastric cancer. Family with sequence similarity 3 member C (FAM3C) is known to play a critical role in inducing epithelial–mesenchymal transition in several cancer types, while its role in gastric cancer is unidentified. The aim of this study was to investigate the role of FAM3C in gastric cancer and provide new information on the receptor tyrosine-kinase pathway and cytokine-based therapies. Methods FAM3C expression was tested in human gastric cancer tissue and adjacent normal mucosa, and the prognostic effect of FAM3C was analyzed in data from the Cancer Genome Atlas (TCGA). The role of FAM3C in gastric cancer proliferation and metastasis was investigated in vitro and in vivo. Western blot analysis and immunofluorescence were used to detect the underlying mechanisms. Results FAM3C expression was increased in gastric cancer tissue and showed cytoplasmic distribution. Gastric cancer patients with FAM3C overexpression had significantly worse prognoses based on TCGA data. In the gastric cancer cell lines MKN45 and AGS, knockdown of FAM3C dramatically attenuated cell migration, but had almost no influence on proliferation, while exogenous FAM3C promoted cell migration in a cell line with low FAM3C expression. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of TCGA data showed that FAM3C was mainly associated with genes involved in focal adhesion, extracellular matrix–receptor interactions and the PI3K–Akt signaling pathway. Knockdown of FAM3C in gastric cancer cell lines significantly suppressed epithelial–mesenchymal transition, as demonstrated by increased expression of E-cadherin and decreased expression of Snail and Slug. Furthermore, knockdown of FAM3C strongly suppressed activation of the PI3K–Akt signaling pathway. Finally, we confirmed that FAM3C knockdown significantly decreased metastatic lesions in vivo. Conclusion Our study demonstrated that FAM3C can promote gastric cancer metastasis both in vitro and in vivo. FAM3C should be taken into consideration for gastric cancer treatments involving inhibition of the ligands and downstream pathways of receptor tyrosine kinases.

[1]  Changjiang Qin,et al.  Sauchinone prevents TGF-β-induced EMT and metastasis in gastric cancer cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Yan Fan,et al.  ILEI is an important intermediate participating in the formation of TGF‐β1–induced renal tubular EMT , 2018, Cell biochemistry and function.

[3]  Bowen Li,et al.  SYNJ2BP promotes the degradation of PTEN through the lysosome-pathway and enhances breast tumor metastasis via PI3K/AKT/SNAI1 signaling , 2017, Oncotarget.

[4]  Muh-Hwa Yang,et al.  Revisiting epithelial‐mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness , 2017, Molecular oncology.

[5]  Q. Mei,et al.  ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways , 2017, Oncotarget.

[6]  Weigang Zhang,et al.  TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT , 2017, Oncotarget.

[7]  Jun Wang,et al.  A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells , 2017, Scientific Reports.

[8]  Q. Cui,et al.  Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice , 2017, Diabetes.

[9]  Q. Gao,et al.  The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin‐like EMT inducer (ILEI) , 2017, IUBMB life.

[10]  Jing Yang,et al.  Epithelial–mesenchymal transition in tumor metastasis , 2016, Molecular oncology.

[11]  M. Tomic-Canic,et al.  Epithelial-mesenchymal transition in tissue repair and fibrosis , 2016, Cell and Tissue Research.

[12]  F. Roviello,et al.  Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. , 2016, Cancer letters.

[13]  Jian-Hua Fu,et al.  Prognostic significance of FAM3C in esophageal squamous cell carcinoma , 2015, Diagnostic Pathology.

[14]  B. Tang,et al.  Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis. , 2015, Cancer letters.

[15]  F. Giostra,et al.  Methods and Results , 2014 .

[16]  Zhe Zhang,et al.  Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer , 2014, Oncotarget.

[17]  P. Gao,et al.  ILEI: a novel marker for epithelial–mesenchymal transition and poor prognosis in colorectal cancer , 2014, Histopathology.

[18]  Karin Aumayr,et al.  Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen–urokinase plasminogen activator receptor system–regulated secretion during breast cancer progression , 2014, Breast Cancer Research.

[19]  E. Thompson,et al.  Targeting EMT in cancer: opportunities for pharmacological intervention. , 2014, Trends in pharmacological sciences.

[20]  S. Jiao,et al.  ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549 , 2014, Tumor Biology.

[21]  Yun-peng Liu,et al.  Pyruvate Kinase M2 Plays a Dual Role on Regulation of the EGF/EGFR Signaling via E-Cadherin-Dependent Manner in Gastric Cancer Cells , 2013, PloS one.

[22]  N. Boku.  HER2-positive gastric cancer , 2013, Gastric Cancer.

[23]  Samy Lamouille,et al.  TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progression , 2013, Current opinion in oncology.

[24]  Li Yang,et al.  Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. , 2011, Gastroenterology.

[25]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[26]  M. Korpal,et al.  The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.

[27]  H. Beug,et al.  ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. , 2006, Cancer cell.

[28]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[29]  Michael A. Briggs,et al.  Cloning, expression, and initial characterization of a novel cytokine-like gene family. , 2002, Genomics.

[30]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.